GlobeNewswire·Nov 12, 2026, 6:50 AM ET

Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update

FDA is reviewing Pharvaris' New Drug Application for deucrictibant IR to treat HAE attacks, with a PDUFA date set for April 23, 2027.
Topline data from part 1 of the CREAATE Phase 3 study evaluating deucrictibant XR for AAE-C1INH prophylaxis is expected in Q1 2027.
Enrollment is ongoing in part 2 of the CREAATE study assessing deucrictibant IR for on-demand treatment of AAE-C1INH attacks.
Pharvaris is preparing the NDA dossier for deucrictibant XR to prevent AE-BK attacks, with a submission timeline targeting the first half of 2027.
The CHAPTER-3 Phase 3 study met all endpoints, showing an 83% reduction in mean monthly HAE attack rates with deucrictibant XR.
Results from the RAPIDe-3 study were published in The Lancet, demonstrating median symptom relief onset in 1.28 hours for deucrictibant IR in HAE patients.
Cash and cash equivalents totaled €283 million as of September 30, 2026, down from €292 million in December 2025.
R&D expenses for the third quarter of 2026 were €32.4 million, while G&A expenses rose to €17.7 million.
The company reported a net loss of €47.4 million for the quarter ended September 30, 2026, or €0.67 per share.
CEO Berndt Modig highlighted progress toward a potential commercial launch and noted upcoming data presentations at the ACAAI Annual Scientific Meeting.